New Catch the Latest Buzz: Weekly News Release Highlights

$WENA ANEW MEDICAL, INC. (NASDAQ: WENA) announced the appointment of Jeffrey LeBlanc as the company’s Chief Financial Officer (CFO), replacing the interim CFO, Edward Cong Wang, who was the former CFO of Redwoods Acquisition Corp into which ANEW merged.

$WENA ANEW MEDICAL, INC. (“ANEW” or the “Company”) (NASDAQ: WENA), announced the signing of an exclusive worldwide license agreement with Transfertech Sherbrooke(“TTS”)regarding Nanoject, a needle-free, freeze-dried nanopowder autoinjector for medicines and vaccines.

$BBLR Bubblr Inc., d/b/a Ethical Web AI (OTC: BBLR) - a front-runner in ethical technology determined to revolutionize the digital domain, has announced that its Ethical Web product is now demonstrable.

The Ethical Web platform has been in development for over three years. It is the technical manifestation of its highly valued granted US patent 10977387. Established internet search engines have not really changed in over 30 years. This new platform allows licensees to build their own super apps in a profoundly different way.

$BCDS BLAQclouds, Inc.(OTC: BCDS) announced the launch of version 1 of its BLAQlp.io DaPP and an update on the recently announced LOI to acquire ZEUS Blockchain Partners, Inc. On August 18, 2024, BLAQclouds unveiled BLAQlp.io. This innovative platform enables private funds, family offices, institutional investors, high-net-worth individuals, and accredited funders to participate in its open-source protocol to create noncustodial liquidity for token projects on the Ethereum and ZEUS Blockchains

$SMCE SMCE (OTC: SMCE), a pioneer in financial technology, proudly announces the launch of Chaintrade.ai, an advanced AI-powered platform designed to revolutionize data intelligence for the capital markets. With a suite of vertically focused AI applications, Chaintrade.ai is set to transform how investors, analysts, and financial institutions access, analyze, and leverage market data, driving smarter decisions and fostering innovation across the industry.

$AMPG AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, today announced the signing of a Memorandum of Understanding (MOU) with a USA based IP Data Networking company to deploy a Private 5G Network in the state of California.

$AMPG AmpliTech Group, Inc (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, today announced the company will host an investor conference call on Wednesday, August 28^th , 2024 at 5:00 PM ET.

$ABQQ AB International Group Corp. (OTC: ABQQ), an intellectual property (IP) and movie investment and licensing firm, announced business updates today.

$LIPO Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotech company, will highlight clinical data on LP-20, a novel MRI contrast agent designed for diagnosing interstitial cystitis and detecting bladder cancer at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ) in Kyoto, Japan, taking place August 21-23, 2024.

$LIPO Lipella Pharmaceuticals, Inc. (NASDAQ: LIPO) has introduced an online registry for Oral Lichen Planus (OLP) patients. This digital platform aims to boost research efforts and facilitate the creation of novel therapies for OLP, a persistent inflammatory condition affecting oral mucous membranes. With symptoms including a burning sensation, white patches, tissue swelling, and ulceration, OLP impacts an estimated 6 million individuals in the United States and currently lacks any FDA-approved treatments

$BSEM BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that the Institutional Review Board (IRB) has approved a clinical study to evaluate Vendaje® for diabetic foot ulcers (DFU), a key product in the company’s placental-derived allograft portfolio. This study aims to assess the efficacy of Vendaje compared to standard of care in diabetic patients with non-healing DFU’s, providing critical data to support both patient outcomes and payer decisions.